Navigation Links
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Date:8/11/2009

SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced viral load data for the final cohort of hepatitis C patients in a Phase I clinical trial of ANA773, the Company's oral inducer of endogenous interferons that acts via the toll-like receptor 7 (TLR7) pathway. In patients who received 2000 mg ANA773 every other day over 10 days, the mean (+/-SEM) maximal decline in viral load was 1.3 (+/-0.4) log10, compared to a mean maximal decline of 0.3 (+/-0.1) log10 in patients who received placebo (p=0.037). Five of the eight patients who received 2000 mg ANA773 experienced a maximal decline of greater than 1 log, while none of the eight patients who received placebo experienced a decline of greater than 1 log (p<0.001 for the proportion of patients with maximal response greater than 1 log compared to placebo). The mean end-of-treatment decline was 0.6 log10 in patients who received 2000 mg ANA773 compared to 0.1 log10 in patients who received placebo. ANA773 was well-tolerated in patients throughout the course of the study and there were no serious adverse events reported.

"ANA773 has demonstrated a significant short-term antiviral response in HCV patients, comparable to many historical reports of interferon as a single agent," commented Steve Worland, Ph.D., Anadys' President and CEO. "Given its oral delivery and favorable tolerability profile to date, we believe that ANA773 holds promise as a potential replacement for injectable interferon products in HCV therapy. We intend to seek partnership opportunities to continue advancing the development of ANA773, with the objective of creating well-tolerated, all oral combination regimens to treat hepatitis C."

James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Ch
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharmas Product Class
2. Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
3. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
4. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
5. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
6. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
7. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
8. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
9. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
10. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
11. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...  The quality function within the medical device sector ... standards at every stage of the product life cycle. ... have the challenge of balancing quality and safety with ... effectively balance these priorities risk funding and staffing for ... regulatory scrutiny. For the third consecutive year, ...
(Date:3/27/2015)... YORK , March 27, 2015 Object ... the blind, visually impaired and elderly. The VelaSense ... these individuals to lead more independent, productive and fulfilling ... Technology which will allow users to identify objects from ... as well as create customized object databases for personal ...
(Date:3/27/2015)... , March 27, 2015 /CNW Telbec/ - Russell ... Research-Based Pharmaceutical Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, ... working group on the biopharmaceutical industry. However, the association ... "We commend the government,s intent to strive ... of measures to promote Quebec,s ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... company update at the Wedbush Life Sciences Conference in New ... Interested parties may access a live audio webcast ... BioMarin website, www.BMRN.com .  A replay of the call ...
... Healthy Advice ® Networks, the nation,s leading provider ... point-of-care, announces that their partner, MediaForce PR, has ... and Drug Administration,s campaign, educating consumers about the ... with MediaForce PR, Healthy Advice Networks ...
Cached Medicine Technology:BioMarin to Present at the Wedbush Life Sciences Conference 2Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 2Healthy Advice® Networks Partners With MediaForce PR to Deliver Public Service Announcements to Educate Consumers About Appropriate Use of Prescription Medications 3
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) pending in the U.S. District ... litigation’s next Case Management Conference for April 21st ... meeting will address the progress of product liability ... experienced heart attacks, strokes and other cardiovascular complications ...
(Date:3/29/2015)... March 29, 2015 North American Seminars ... PT Online Continuing Education Courses . , ... of CME - TPTA, approval # 56399TX      , ... of the shoulder complex - 10.5 hours - Texas ... , Examination and Treatment of the SI Joint - ...
(Date:3/28/2015)... Could genetic code determine someone’s coffee habit? Apparently ... researchers at the Harvard T.H. Chan School of Public ... Coffee and Caffeine Genetics Consortium and published ... study—one of several recent HSPH investigations of the popular ... 120,000 regular coffee drinkers of European and African ancestry. ...
(Date:3/28/2015)... York, New York (PRWEB) March 28, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. Bard, ... litigation underway in U.S. District Court, Southern District ... S. Grand, is serving on the Plaintiffs’ Steering ... 24th, the Court has granted certain defendants named ...
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 An ... a problem which could prove critical to organizations that ... testing, a critical aspect of data security, is worsening ... industry data security report, every major category out of ... and penetration testing. “With all the craziness that has ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4
... ... Bill McKee,s Role Expanded, MONTVALE, N.J., March ... the restructuring of its,senior management team to better align the ... the global organization. Barr,s Chairman and Chief Executive,Officer, Bruce L. ...
... omega-3,polyunsaturated fatty acids (PUFAs) continue to prove their ... recent research summarized in the March,2008 Fats of ... show that omega-3s may improve recovery from,spinal cord ... of fish oil consumption on arterial elasticity, which ...
... of the California Department of Health Service,s Medi-Cal Managed Care ... widespread health care disparities based on ethnicity, race and language ... are bearing the brunt of it. , ... for the state,s minority populations, resulting in poorer health for ...
... March 27 A new survey shows that more ... cloned food after,the recent approval of the Food and ... Seas Research, 77.8 percent of,respondents said they were unsure ... making a decision. Many respondents referred to,Dolly, the first ...
... On March 25, 2008, The Honorable Dan,A. Polster, ... Liability Multi-District Litigation in the Northern District,of Ohio, ... Steering,Committee. One of these lawyers is Peter Burg ... Polster, and is responsible for conducting,pre-trial proceedings on ...
... the leader in,physician education for cardiac CT imaging, ... reduce the radiation dose to patients during,a CT ... CTA,are in the low dose ranges, well below ... health risk. However, if physicians and technologists are ...
Cached Medicine News:Health News:Barr Announces Reorganization of Senior Management, Business Functions 2Health News:Barr Announces Reorganization of Senior Management, Business Functions 3Health News:Barr Announces Reorganization of Senior Management, Business Functions 4Health News:Barr Announces Reorganization of Senior Management, Business Functions 5Health News:Barr Announces Reorganization of Senior Management, Business Functions 6Health News:Barr Announces Reorganization of Senior Management, Business Functions 7Health News:Omega-3 Fatty Acids Protect the Spinal Cord, Heart, Brain and Eyes 2Health News:Study finds widespread care disparities in Medi-Cal program 2Health News:Study finds widespread care disparities in Medi-Cal program 3Health News:CVCTA Education Announces New LOW DOSE Initiative for CT Angiograms 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: